Portfolio of Genetic Testing Stocks

Here are 8 genetic testing stocks.

8 Genetic Testing Stocks

Stock Returns & Price Chart

Symbol

Recent Prices &
Annualized Return

Genomic HealthGHDX
Cancer GeneticsCGIX
Exact SciencesEXAS
Genetic Technologies LtdGENE
HTG Molecular DiagnosticsHTGM
InvitaeNVTA
NateraNTRA
VeracyteVCYT
Price data from Quandl as of most recent close.


To inspect the performance of the Genetic Testing Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Quandl.

The 3 stocks included in the portfolio computations are: GHDX, EXAS and GENE. The current value of the portfolio assumes that $3,333.33 was invested (total of $10,000) in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends. The 5 stocks excluded from the portfolio computations because of insufficient price data are: CGIX, HTGM, NVTA, NTRA and VCYT.

The current value of a $10,000 investment is $139,127. The percent return is 1,291.27%. The annualized return is 30.12%.




Return Summary for Genetic Testing Stocks
Start DateSep-30-2009
Start Investment$10,000.00
End DateSep-13-2019
Current Value of Investment$139,127.28
Total Return1,291.27%
Annualized Return30.12%
Min DateOct-30-2009
Min Price$8,850.76
Max DateAug-30-2019
Max Price$154,863.32
# Values121
Number Returns7,260
Number Profitable Returns5,904
Percent Profitable Returns81.32%
Number Unprofitable Returns1,356
Percent Unprofitable Returns18.68%
Profitable to Unprofitable Returns Ratio4.35



NOTE: The stocks included in the tables and chart are representative of the industry. They are not recommendations.


Related Portfolios

Portfolio of Gene Editing (CRISPR) Stocks

Portfolio of Genomics Stocks

Portfolio of Stem Cell Stocks